UK tissue regulator's fees "will deter small companies"
This article was originally published in Scrip
Organisations representing UK companies in the life sciences sector say that the Human Tissue Authority's new fees are "unrealistically excessive" and that the 2009-10 fee schedule is being implemented after a consultation process that was "conducted with a lack of rigour".
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.